Glycosylated fibronectin improves first‐trimester prediction of pre‐eclampsia
Authors: Moungmaithong S. , Wang X. , Lau C. S. L. , Tse A. W. T. , Lee N. M. W. , Leung H. H. Y. , Poon L. C. , Sahota D. S. 
Published: August 2023

Objective

To determine whether maternal serum glycosylated fibronectin (GlyFn) level in the first trimester increases the sensitivity of the Fetal Medicine Foundation (FMF) triple test, which incorporates mean arterial pressure, uterine artery pulsatility index and placental growth factor, when screening for pre‐eclampsia (PE) in an Asian population.

Methods

This was a nested case–control study of Chinese women with a singleton pregnancy who were screened for PE at 11–13 weeks' gestation as part of a non‐intervention study between December 2016 and June 2018. GlyFn levels were measured retrospectively in archived serum from 1685 pregnancies, including 101 with PE, using an enzyme‐linked immunosorbent assay (ELISA), and from 448 pregnancies, including 101 with PE, using a point‐of‐care (POC) device. Concordance between ELISA and POC tests was assessed using Lin's correlation coefficient and Passing–Bablok and Bland–Altman analyses. GlyFn was transformed into multiples of the median (MoM) to adjust for maternal and pregnancy characteristics. GlyFn MoM was compared between PE and non‐PE pregnancies, and the association between GlyFn MoM and gestational age at delivery with PE was assessed. Risk for developing PE was estimated using the FMF competing‐risks model. Screening performance for preterm and any‐onset PE using different biomarker combinations was quantified by area under the receiver‐operating‐characteristics curve (AUC) and detection rate (DR) at a 10% fixed false‐positive rate (FPR). Differences in AUC between biomarker combinations were compared using the DeLong test.

Results

The concordance correlation coefficient between ELISA and POC measurements was 0.86 (95% CI, 0.83–0.88). Passing–Bablok analysis indicated proportional bias (slope, 1.08 (95% CI, 1.04–1.14)), with POC GlyFn being significantly higher compared with ELISA GlyFn. ELISA GlyFn in non‐PE pregnancies was independent of gestational age at screening (P = 0.11), but significantly dependent on maternal age (P < 0.003), weight (P < 0.0002), height (P = 0.001), parity (P < 0.02) and smoking status (P = 0.002). Compared with non‐PE pregnancies, median GlyFn MoM using ELISA and POC testing was elevated significantly in those with preterm PE (1.23 vs 1.00; P < 0.0001 and 1.18 vs 1.00; P < 0.0001, respectively) and those with term PE (1.26 vs 1.00; P < 0.0001 and 1.22 vs 1.00; P < 0.0001, respectively). GlyFn MoM was not correlated with gestational age at delivery with PE (P = 0.989). Adding GlyFn to the FMF triple test for preterm PE increased significantly the AUC from 0.859 to 0.896 (P = 0.012) and increased the DR at 10% FPR from 64.9% (95% CI, 48.7–81.1%) to 82.9% (95% CI, 66.4–93.4%). The corresponding DRs at 10% FPR for any‐onset PE were 52.5% (95% CI, 42.3–62.5%) and 65.4% (95% CI, 55.2–74.5%), respectively.

Conclusions

Adding GlyFn to the FMF triple test increased the screening sensitivity for both preterm and any‐onset PE in an Asian population. Prospective non‐intervention studies are needed to confirm these initial findings. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.